Skip to main navigation
logo
  • Overview
  • News & Events
    • Press Releases
    • Events and Presentations
  • Stock Information
    • Stock Quote & Chart
    • Analyst Coverage
  • Financials
    • SEC Filings
    • Annual Reports
    • Quarterly Releases
  • Governance
    • Governance Overview
    • Board of Directors
    • Management
    • Committee Composition
  • IR Resources
    • Email Alerts
    • Contact IR

Press Releases

Press Releases

Recent Releases

September 6, 2022
Athira Pharma Provides Update on Plans for Ongoing LIFT-AD Clinical Study of Fosgonimeton in Mild-to-Moderate Alzheimer’s Patients

August 15, 2022
Athira Pharma Reports Second Quarter 2022 Financial Results and Recent Clinical and Corporate Updates

August 3, 2022
Athira Pharma Presents Data from ACT-AD Phase 2 Proof-of-Concept Clinical Study of Fosgonimeton in Mild-to-Moderate Alzheimer’s Patients at the Alzheimer's Association International Conference 2022

Press Releases
January 19, 2021
Athira Pharma Announces Proposed Public Offering of Common Stock
January 7, 2021
Athira Pharma to Present at the 39th Annual J.P. Morgan Healthcare Conference
December 14, 2020
Athira Pharma Announces Appointment of Kelly A. Romano to its Board of Directors
December 8, 2020
Athira Pharma Awarded $15 Million Grant from National Institute on Aging to Support ACT-AD Clinical Trial in Alzheimer’s Disease
December 1, 2020
Athira Pharma Announces Initiation of Patient Dosing for ACT-AD Clinical Trial of ATH-1017, Small Molecule HGF/MET Activator, for Treatment of Mild-to-Moderate Alzheimer’s Disease
November 12, 2020
Athira Pharma Reports Third Quarter 2020 Financial Results and Provides Business Highlights
November 10, 2020
Athira Pharma to Present at Upcoming November Investor Conferences
October 21, 2020
Athira Pharma to Host Educational Webinar on the Predictive Nature of P300 to Determine Clinical Benefit of Alzheimer’s Disease Treatments
October 1, 2020
Athira Pharma Announces Initiation of Patient Dosing for the LIFT-AD Study, a Phase 2/3 Clinical Trial to Evaluate ATH-1017 for Treatment of Mild-to-Moderate Alzheimer's Disease
September 22, 2020
Athira Pharma Announces Closing of Initial Public Offering

Pagination

  • First page « first
  • Previous page ‹ previous
  • Page 1
  • Page 2
  • Page 3
  • Page 4
  • Page 5
  • Page 6
  • Current page 7
  • Page 8
  • Page 9
  • Next page next ›
  • Last page last »
Displaying 61 - 70 of 81
< SIGN UP FOR EMAIL ALERTS
CONTACT IR

Athira Pharma, Inc.
18706 North Creek Parkway
Suite 104
Bothell, WA 98011

Main line: (866) 725-0930
Local number: (425) 620-8501
info@athira.com

FCOI Policy

Privacy Policy

© Athira Pharma, Inc. All rights reserved.